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Preamble
The medical profession should play a central role in evalu-
ating the evidence related to drugs, devices, and procedures
for the detection, management, and prevention of disease.
When properly applied, expert analysis of available data on
the benefits and risks of these therapies and procedures can
improve the quality of care, optimize patient outcomes, and
favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approach to a
thorough review of evidence has resulted in the production
of clinical practice guidelines that assist physicians in select-
ing the best management strategy for an individual patient.
Moreover, clinical practice guidelines can provide a foun-
dation for other applications, such as performance measures,
appropriate use criteria, and both quality improvement and
clinical decision support tools.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
produced guidelines in the area of cardiovascular disease
since 1980. The ACCF/AHA Task Force on Practice
Guidelines (Task Force), charged with developing, up-
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diseases and procedures, directs and oversees this effort.
Writing committees are charged with regularly reviewing
and evaluating all available evidence to develop balanced,
patient-centric recommendations for clinical practice.
Experts in the subject under consideration are selected by
the ACCF and AHA to examine subject-specific data and
write guidelines in partnership with representatives from
other medical organizations and specialty groups. Writing
committees are asked to perform a formal literature review;
weigh the strength of evidence for or against particular tests,
treatments, or procedures; and include estimates of expected
outcomes where such data exist. Patient-specific modifiers,
comorbidities, and issues of patient preference that may
influence the choice of tests or therapies are considered.
When available, information from studies on cost is con-
sidered, but data on efficacy and outcomes constitute the
primary basis for the recommendations contained herein.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force (1). The
lass of Recommendation (COR) is an estimate of the size
f the treatment effect considering risks versus benefits in
ddition to evidence and/or agreement that a given treat-
ent or procedure is or is not useful/effective or in some
ituations may cause harm. The Level of Evidence (LOE) is
n estimate of the certainty or precision of the treatment
ffect. The writing committee reviews and ranks evidence
upporting each recommendation with the weight of evi-
ence ranked as LOE A, B, or C according to specific
efinitions that are included in Table 1. Studies are identi-
ed as observational, retrospective, prospective, or random-
zed where appropriate. For certain conditions for which
nadequate data are available, recommendations are based
n expert consensus and clinical experience and are ranked
s LOE C. When recommendations at LOE C are sup-
orted by historical clinical data, appropriate references
including clinical reviews) are cited if available. For issues
or which sparse data are available, a survey of current
ractice among the clinicians on the writing committee is
he basis for LOE C recommendations and no references
re cited. The schema for COR and LOE is summarized in
able 1, which also provides suggested phrases for writing
ecommendations within each COR. A new addition to
his methodology is separation of the Class III recom-
endations to delineate if the recommendation is deter-
ined to be of “no benefit” or is associated with “harm”
o the patient. In addition, in view of the increasing
umber of comparative effectiveness studies, comparator
erbs and suggested phrases for writing recommendations
or the comparative effectiveness of one treatment or
trategy versus another have been added for COR I and
Ia, LOE A or B only.
In view of the advances in medical therapy across the
pectrum of cardiovascular diseases, the Task Force has
esignated the term guideline-directed medical therapy t(GDMT) to represent optimal medical therapy as defined by
ACCF/AHA guideline recommended therapies (primarily
Class I). This new term, GDMT, will be used herein and
throughout all future guidelines.
Because the ACCF/AHA practice guidelines address
patient populations (and healthcare providers) residing in
North America, drugs that are not currently available in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, each writing committee reviews the
potential influence of different practice patterns and patient
populations on the treatment effect and relevance to the
ACCF/AHA target population to determine whether the
findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to
assist healthcare providers in clinical decision making by
describing a range of generally acceptable approaches to the
diagnosis, management, and prevention of specific diseases
or conditions. The guidelines attempt to define practices
that meet the needs of most patients in most circumstances.
The ultimate judgment regarding care of a particular patient
must be made by the healthcare provider and patient in light
of all the circumstances presented by that patient. As a
result, situations may arise for which deviations from these
guidelines may be appropriate. Clinical decision making
should involve consideration of the quality and availability
of expertise in the area where care is provided. When these
guidelines are used as the basis for regulatory or payer
decisions, the goal should be improvement in quality of care.
The Task Force recognizes that situations arise in which
additional data are needed to inform patient care more
effectively; these areas will be identified within each respec-
tive guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because lack
of patient understanding and adherence may adversely affect
outcomes, physicians and other healthcare providers should
make every effort to engage the patient’s active participation
in prescribed medical regimens and lifestyles. In addition,
patients should be informed of the risks, benefits, and
alternatives to a particular treatment and be involved in
shared decision making whenever feasible, particularly for
COR IIa and IIb, where the benefit-to-risk ratio may be
lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conflicts of interest that may arise as
a result of industry relationships or personal interests among
the members of the writing committee. All writing com-
mittee members and peer reviewers of the guideline are
required to disclose all such current relationships, as well as
those existing 12 months previously. In December 2009, the
ACCF and AHA implemented a new policy for relation-
ships with industry and other entities (RWI) that requires
the writing committee chair plus a minimum of 50% of the
writing committee to have no relevant RWI (Appendix 1 for
he ACCF/AHA definition of relevance). These statements
Level o
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conference call and/or meeting of the writing committee
and are updated as changes occur. All guideline recommen-
dations require a confidential vote by the writing committee
and must be approved by a consensus of the voting mem-
bers. Members are not permitted to write, and must recuse
themselves from voting on, any recommendation or section
to which their RWI apply. Members who recused them-
selves from voting are indicated in the list of writing commit-
tee members, and section recusals are noted in Appendix 1.
Authors’ and peer reviewers’ RWI pertinent to this guideline
are disclosed in Appendixes 1 and 2, respectively. Additionally,
to ensure complete transparency, writing committee members’
Table 1. Applying Classification of Recommendations and Lev
A recommendation with Level of Evidence B or C does not imply that the recommendation is w
trials. Although randomized trials are unavailable, there may be a very clear clinical consensus
*Data available from clinical trials or registries about the usefulness/efficacy in different subp
failure, and prior aspirin use. †For comparative effectiveness recommendations (Class I and IIa;
comparisons of the treatments or strategies being evaluated.comprehensive disclosure information—including RWI notpertinent to this document—is available as an online supple-
ment. Comprehensive disclosure information for the Task
Force is also available online at www.cardiosource.org/ACC/
About-ACC/Leadership/Guidelines-and-Documents-Task-
Forces.aspx. The work of the writing committee was sup-
ported exclusively by the ACCF, AHA, and the Society for
Cardiovascular Angiography and Interventions (SCAI)
without commercial support. Writing committee members
volunteered their time for this activity.
In an effort to maintain relevance at the point of care for
practicing physicians, the Task Force continues to oversee
an ongoing process improvement initiative. As a result, in
response to pilot projects, several changes to these guide-
Evidence
ny important clinical questions addressed in the guidelines do not lend themselves to clinical
particular test or therapy is useful or effective.
ons, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
f Evidence A and B only), studies that support the use of comparator verbs should involve directel of
eak. Ma
that a
opulatilines will be apparent, including limited narrative text, a
l
s
c
m
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b
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linked to abstracts in PubMed), and more liberal use of
summary recommendation tables (with references that sup-
port LOE) to serve as a quick reference.
In April 2011 the Institute of Medicine released 2
reports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We Can
Trust (2,3). It is noteworthy that the ACCF/AHA guide-
ines are cited as being compliant with many of the proposed
tandards. A thorough review of these reports and of our
urrent methodology is under way, with further enhance-
ents anticipated.
The recommendations in this guideline are considered
urrent until they are superseded by a focused update or the
ull-text guideline is revised. Guidelines are official policy of
oth the ACCF and AHA.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Review
The recommendations listed in this document are, whenever
possible, evidence based. An extensive evidence review was
conducted through November 2010, as well as selected other
references through August 2011. Searches were limited to
studies, reviews, and other evidence conducted in human
subjects and that were published in English. Key search words
included but were not limited to the following: ad hoc angio-
plasty, angioplasty, balloon angioplasty, clinical trial, coronary
stenting, delayed angioplasty, meta-analysis, percutaneous translu-
minal coronary angioplasty, randomized controlled trial, percuta-
neous coronary intervention (PCI) and angina, angina reduction,
antiplatelet therapy, bare-metal stents (BMS), cardiac rehabilita-
tion, chronic stable angina, complication, coronary bifurcation
lesion, coronary calcified lesion, coronary chronic total occlusion,
coronary ostial lesions, coronary stent (BMS and drug-eluting
stents [DES]; and BMS versus DES), diabetes, distal emboliza-
tion, distal protection, elderly, ethics, late stent thrombosis, medical
therapy, microembolization, mortality, multiple lesions, multives-
sel, myocardial infarction, non–ST-elevation myocardial infarction
(NSTEMI), no-reflow, optical coherence tomography, proton
pump inhibitor, return to work, same-day angioplasty and/or
stenting, slow flow, stable ischemic heart disease (SIHD), staged
angioplasty, STEMI, survival, and unstable angina (UA).
Additional searches cross-referenced these topics with the
following subtopics: anticoagulant therapy, contrast nephrop-
athy, PCI-related vascular complications, unprotected left main
PCI, multivessel coronary artery disease (CAD), adjunctive
percutaneous interventional devices, percutaneous hemodynamic
support devices, and secondary prevention. Additionally, the
committee reviewed documents related to the subject matter
previously published by the ACCF and AHA. References
selected and published in this document are representative
and not all-inclusive.Because the executive summary contains only the recom-
mendations, the reader is encouraged to consult the full-text
guideline (4) for additional detail on the recommendations
and guidance on the care of the patient undergoing PCI.
1.2. Organization of the Writing Committee
The committee was composed of physicians with expertise
in interventional cardiology, general cardiology, critical care
cardiology, cardiothoracic surgery, clinical trials, and health
services research. The committee included representatives
from the ACCF, AHA, and SCAI.
1.3. Document Review and Approval
This document was reviewed by 2 official reviewers nomi-
nated by the ACCF, AHA, and SCAI, as well as 21
individual content reviewers (including members of the
ACCF Interventional Scientific Council and ACCF Sur-
geons’ Scientific Council). All information on reviewers’
RWI was distributed to the writing committee and is
published in this document (Appendix 2). This document
was approved for publication by the governing bodies of the
ACCF, AHA, and SCAI.
1.4. PCI Guideline Scope
The evolution of the PCI guideline reflects the growth of
knowledge in the field and parallels the many advances and
innovations in the field of interventional cardiology, includ-
ing primary PCI, BMS and DES, intravascular ultrasound
(IVUS) and physiologic assessments of stenosis, and newer
antiplatelet and anticoagulant therapies. The 2011 iteration
of the guideline continues this process, addressing ethical
aspects of PCI, vascular access considerations, CAD revas-
cularization including hybrid revascularization, revascular-
ization before noncardiac surgery, optical coherence tomog-
raphy, advanced hemodynamic support devices, no-reflow
therapies, and vascular closure devices. Most of this docu-
ment is organized according to “patient flow,” consisting of
preprocedural considerations, procedural considerations,
and postprocedural considerations. The focus of this guide-
line is the safe, appropriate, and efficacious performance of
PCI. The risks of PCI must be balanced against the
likelihood of improved survival, symptoms, or functional
status. This is especially important in patients with SIHD.
In a major undertaking, the STEMI, PCI, and coronary
artery bypass graft (CABG) surgery guidelines were written
concurrently, with additional collaboration with the SIHD
guideline writing committee, allowing greater collaboration
between the different writing committees on topics such as
PCI in STEMI and revascularization strategies in patients
with CAD (including unprotected left main PCI, multives-
sel disease revascularization, and hybrid procedures).
In accordance with direction from the Task Force and
feedback from readers, in this iteration of the guideline, the text
has been shortened, with an emphasis on summary statements
rather than detailed discussion of numerous individual trials.
23
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created to document the studies and data considered for new or
changed guideline recommendations.
2. CAD Revascularization: Recommendations
Recommendations and text in this section are the result of
extensive collaborative discussions between the PCI and
CABG writing committees, as well as key members of the
SIHD and UA/NSTEMI writing committees. Certain
issues, such as older versus more contemporary studies,
primary analyses versus subgroup analyses, and prospective
versus post hoc analyses, have been carefully weighed in
designating COR and LOE; they are addressed in the
appropriate corresponding text (4). The goals of revascular-
ization for patients with CAD are to 1) improve survival
and/or 2) relieve symptoms. The following text contains
recommendations for revascularization to improve survival
and symptoms, and they are presented in Tables 2 and 3.
Revascularization recommendations in this section are
predominantly based on studies of patients with symptom-
atic SIHD and should be interpreted in this context. As
discussed later in this section, recommendations on the type
of revascularization are, in general, applicable to patients
with UA/NSTEMI. In some cases (e.g., unprotected left
main CAD), specific recommendations are made for pa-
tients with UA/NSTEMI or STEMI.
2.1. Heart Team Approach
to Revascularization Decisions
CLASS I
1. A Heart Team approach to revascularization is recommended in
patients with unprotected left main or complex CAD (5–7). (Level of
Evidence: C)
CLASS IIa
1. Calculation of the Society of Thoracic Surgeons and SYNTAX (Syn-
ergy between Percutaneous Coronary Intervention with TAXUS and
Cardiac Surgery) scores is reasonable in patients with unprotected
left main and complex CAD (7–14). (Level of Evidence: B)
2.2. Revascularization to Improve Survival
Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is recommended for patients with signif-
icant (50% diameter stenosis) left main coronary artery stenosis
(15–21). (Level of Evidence: B)
CLASS IIa
1. PCI to improve survival is reasonable as an alternative to CABG in
selected stable patients with significant (50% diameter stenosis)
unprotected left main CAD with: 1) anatomic conditions associated
with a low risk of PCI procedural complications and a high likelihood
of good long-term outcome (e.g., a low SYNTAX score [22], ostial
or trunk left main CAD); and 2) clinical characteristics that predict a
significantly increased risk of adverse surgical outcomes (e.g.,
Society of Thoracic Surgeons–predicted risk of operative mortality
5%) (8,10,11,22–40,106) (Level of Evidence: B). PCI to improve survival is reasonable in patients with UA/NSTEMI
when an unprotected left main coronary artery is the culprit lesion
and the patient is not a candidate for CABG (11,27,29–31,36,
37,39–41). (Level of Evidence: B)
. PCI to improve survival is reasonable in patients with acute STEMI
when an unprotected left main coronary artery is the culprit lesion,
distal coronary flow is less than TIMI (Thrombolysis In Myocardial
Infarction) grade 3, and PCI can be performed more rapidly and
safely than CABG (24,42,43). (Level of Evidence: C)
CLASS IIb
1. PCI to improve survival may be reasonable as an alternative to
CABG in selected stable patients with significant (50% diameter
stenosis) unprotected left main CAD with: 1) anatomic conditions
associated with a low to intermediate risk of PCI procedural com-
plications and an intermediate to high likelihood of good long-term
outcome (e.g., low-intermediate SYNTAX score of 33, bifurcation
left main CAD); and 2) clinical characteristics that predict an
increased risk of adverse surgical outcomes (e.g., moderate-severe
chronic obstructive pulmonary disease, disability from previous
stroke, or previous cardiac surgery; Society of Thoracic Surgeons–
predicted risk of operative mortality 2%) (8,10,11,22–40,44).
(Level of Evidence: B)
CLASS III: HARM
1. PCI to improve survival should not be performed in stable patients
with significant (50% diameter stenosis) unprotected left main
CAD who have unfavorable anatomy for PCI and who are good
candidates for CABG (8,10,11,15–23). (Level of Evidence: B)
Non–Left Main CAD Revascularization
CLASS I
1. CABG to improve survival is beneficial in patients with significant
(70% diameter) stenoses in 3 major coronary arteries (with or
without involvement of the proximal left anterior descending [LAD])
or in the proximal LAD plus 1 other major coronary artery
(17,21,45–48). (Level of Evidence: B)
2. CABG or PCI to improve survival is beneficial in survivors of sudden
cardiac death with presumed ischemia-mediated ventricular tachy-
cardia caused by significant (70% diameter) stenosis in a major
coronary artery. (CABG Level of Evidence: B [49–51]; PCI Level of
Evidence: C [49])
CLASS IIa
1. CABG to improve survival is reasonable in patients with significant
(70% diameter) stenoses in 2 major coronary arteries with severe
or extensive myocardial ischemia (e.g., high-risk criteria on stress
testing, abnormal intracoronary hemodynamic evaluation, or20%
perfusion defect by myocardial perfusion stress imaging) or target
vessels supplying a large area of viable myocardium (52–55). (Level
of Evidence: B)
2. CABG to improve survival is reasonable in patients with mild-
moderate left ventricular systolic dysfunction (ejection fraction 35%
to 50%) and significant (70% diameter stenosis) multivessel CAD
or proximal LAD coronary artery stenosis, when viable myocardium
is present in the region of intended revascularization (21,56–60).
(Level of Evidence: B)
3. CABG with a left internal mammary artery graft to improve survival
is reasonable in patients with significant (70% diameter) stenosis
in the proximal LAD artery and evidence of extensive ischemia
(21,48,61,62). (Level of Evidence: B)
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Anatomic
Setting COR LOE References
UPLM or complex CAD
CABG and
PCI
I—Heart Team approach recommended C (5–7)
CABG and
PCI
IIa—Calculation of STS and SYNTAX scores B (7–14)
UPLM*
CABG I B (15–21)
PCI IIa—For SIHD when both of the following are present:
● Anatomic conditions associated with a low risk of PCI procedural complications and a high likelihood
of good long-term outcome (e.g., a low SYNTAX score of 22, ostial or trunk left main CAD)
● Clinical characteristics that predict a significantly increased risk of adverse surgical outcomes
(e.g., STS-predicted risk of operative mortality 5%)
B (8,10,11,22–40,106)
IIa—For UA/NSTEMI if not a CABG candidate B (11,27,29–31,36,37,
39–41)
IIa—For STEMI when distal coronary flow is TIMI flow grade 3 and PCI can be performed more rapidly
and safely than CABG
C (24,42,43)
IIb—For SIHD when both of the following are present:
● Anatomic conditions associated with a low to intermediate risk of PCI procedural complications and
an intermediate to high likelihood of good long-term outcome (e.g. low-intermediate SYNTAX score of
33, bifurcation left main CAD)
● Clinical characteristics that predict an increased risk of adverse surgical outcomes (e.g., moderate-
severe COPD, disability from prior stroke, or prior cardiac surgery; STS-predicted risk of operative
mortality 2%)
B (8,10,11,22–40,44)
III: Harm—For SIHD in patients (versus performing CABG) with unfavorable anatomy for PCI and who are
good candidates for CABG
B (8,10,11,15–23)
3-vessel disease with or without proximal LAD artery disease*
CABG I B (17,21,45–48)
IIa—It is reasonable to choose CABG over PCI in patients with complex 3-vessel CAD (e.g., SYNTAX score
22) who are good candidates for CABG.
B (23,38,48,63,64)
PCI IIb—Of uncertain benefit B (17,45,48,74)
2-vessel disease with proximal LAD artery disease*
CABG I B (17,21,45–48)
PCI IIb—Of uncertain benefit B (17,45,48,74)
2-vessel disease without proximal LAD artery disease*
CABG IIa—With extensive ischemia B (52–55)
IIb—Of uncertain benefit without extensive ischemia C (48)
PCI IIb—Of uncertain benefit B (17,45,48,74)
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term benefit B (21,48,61,62)
PCI IIb—Of uncertain benefit B (17,45,48,74)
1-vessel disease without proximal LAD artery involvement
CABG III: Harm B (21,45,52,53,86–90)
PCI III: Harm B (21,45,52,53,86–90)
LV dysfunction
CABG IIa—EF 35% to 50% B (21,56–60)
CABG IIb—EF 35% without significant left main CAD B (21,56–60,75,76)
PCI Insufficient data N/A
Survivors of sudden cardiac death with presumed ischemia-mediated VT
CABG I B (49–51)
PCI I C (49)
No anatomic or physiologic criteria for revascularization
CABG III: Harm B (21,45,52,53,86–90)
PCI III: Harm B (21,45,52,53,86–90)
*In patients with multivessel disease who also have diabetes, it is reasonable to choose CABG (with LIMA) over PCI (54,66–73) (Class IIa; LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, class of recommendation; EF, ejection fraction; LAD, left anterior
escending; LIMA, left internal mammary artery; LOE, level of evidence; LV, left ventricular; N/A, not applicable; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; STEMI,
T-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIMI, Thrombolysis In Myocardial
nfarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; UPLM, unprotected left main disease; and VT, ventricular tachycardia.
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with complex 3-vessel CAD (e.g., SYNTAX score 22) with or without
involvement of the proximal LAD artery who are good candidates for
CABG (23,38,48,63,64). (Level of Evidence: B)
. CABG is probably recommended in preference to PCI to improve
survival in patients with multivessel CAD and diabetes mellitus, partic-
ularly if a left internal mammary artery graft can be anastomosed to
the LAD artery (54,66–73). (Level of Evidence: B)
CLASS IIb
1. The usefulness of CABG to improve survival is uncertain in patients
with significant (70%) stenoses in 2 major coronary arteries not
involving the proximal LAD artery and without extensive ischemia
(48). (Level of Evidence: C)
2. The usefulness of PCI to improve survival is uncertain in patients
with 2- or 3-vessel CAD (with or without involvement of the proximal
LAD artery) or 1-vessel proximal LAD disease (17,45,48,74). (Level
of Evidence: B)
3. CABG might be considered with the primary or sole intent of
improving survival in patients with SIHD with severe left ventricular
systolic dysfunction (ejection fraction 35%) whether or not viable
myocardium is present (21,56–60,75,76). (Level of Evidence: B)
4. The usefulness of CABG or PCI to improve survival is uncertain in
patients with previous CABG and extensive anterior wall ischemia
on noninvasive testing (77–85). (Level of Evidence: B)
CLASS III: HARM
1. CABG or PCI should not be performed with the primary or sole intent to
improve survival in patients with SIHD with 1 or more coronary steno-
ses that are not anatomically or functionally significant (e.g., 70%
diameter non–left main coronary artery stenosis, fractional flow re-
serve0.80, no or only mild ischemia on noninvasive testing), involve
only the left circumflex or right coronary artery, or subtend only a small
area of viablemyocardium (21,45,52,53,86–90). (Level of Evidence: B)
2.3. Revascularization to Improve Symptoms
CLASS I
1. CABG or PCI to improve symptoms is beneficial in patients with 1 or
more significant (70% diameter) coronary artery stenoses ame-
nable to revascularization and unacceptable angina despite GDMT
Table 3. Revascularization to Improve Symptoms With Signific
r Physiological (FFR<0.80) Coronary Artery Stenoses
Clinical Setting
1 significant stenoses amenable to revascularization and unacceptable a
despite GDMT
1 significant stenoses and unacceptable angina in whom GDMT cannot b
implemented because of medication contraindications, adverse effects,
patient preferences
Previous CABG with 1 significant stenoses associated with ischemia and
unacceptable angina despite GDMT
Complex 3-vessel CAD (e.g., SYNTAX score 22) with or without involveme
proximal LAD artery and a good candidate for CABG
Viable ischemic myocardium that is perfused by coronary arteries that are
amenable to grafting
No anatomic or physiologic criteria for revascularization
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COR, class of recommen
not applicable; PCI, percutaneous coronary intervention; SYNTAX, Synergy between Percutaneous C(74,91–100). (Level of Evidence: A)CLASS IIa
1. CABG or PCI to improve symptoms is reasonable in patients with 1
or more significant (70% diameter) coronary artery stenoses and
unacceptable angina for whom GDMT cannot be implemented
because of medication contraindications, adverse effects, or patient
preferences. (Level of Evidence: C)
2. PCI to improve symptoms is reasonable in patients with previous
CABG, 1 or more significant (70% diameter) coronary artery
stenoses associated with ischemia, and unacceptable angina de-
spite GDMT (78,81,84). (Level of Evidence: C)
. It is reasonable to choose CABG over PCI to improve symptoms in
patients with complex 3-vessel CAD (e.g., SYNTAX score 22), with
or without involvement of the proximal LAD artery who are good
candidates for CABG (23,38,48,63,64). (Level of Evidence: B)
CLASS IIb
1. CABG to improve symptoms might be reasonable for patients with
previous CABG, 1 or more significant (70% diameter) coronary
artery stenoses not amenable to PCI, and unacceptable angina
despite GDMT (85). (Level of Evidence: C)
. Transmyocardial laser revascularization performed as an adjunct to
CABG to improve symptoms may be reasonable in patients with
viable ischemicmyocardium that is perfused by arteries that are not
amenable to grafting (101–105). (Level of Evidence: B)
CLASS III: HARM
1. CABG or PCI to improve symptoms should not be performed in
patients who do not meet anatomic (50% left main or 70%
non–left main stenosis) or physiological (e.g., abnormal fractional
flow reserve) criteria for revascularization. (Level of Evidence: C)
2.4. Clinical Factors That May Influence the Choice
of Revascularization
2.4.1. Dual Antiplatelet Therapy Compliance and
Stent Thrombosis
CLASS III: HARM
1. PCI with coronary stenting (BMS or DES) should not be performed if the
patient is not likely to be able to tolerate and complywith dual antiplatelet
therapy (DAPT) for the appropriate duration of treatment based on the
natomic (>50% Left Main or >70% Non–Left Main CAD)
COR LOE References
ICABG
IPCI
A (74,91–100)
IIaCABG
IIaPCI
C N/A
IIaPCI C (78,81,84)
IIbCABG C (85)
the IIaCABG preferred
over PCI
B (23,38,48,63,64)
IIbTMR as an
adjunct to CABG
B (101–105)
III: HarmCABG
III: HarmPCI
C N/A
FFR, fractional flow reserve; GDMT, guideline-directed medical therapy; LOE, level of evidence; N/A,
Intervention with TAXUS and Cardiac Surgery; and TMR, transmyocardial laser revascularization.ant A
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CLASS IIa
1. Hybrid coronary revascularization (defined as the planned combina-
tion of left internal mammary artery-to-LAD artery grafting and PCI of
1 non-LAD coronary arteries) is reasonable in patients with 1 ormore
of the following (111–117) (Level of Evidence: B):
a. Limitations to traditional CABG, such as heavily calcified proxi-
mal aorta or poor target vessels for CABG (but amenable to PCI);
b. Lack of suitable graft conduits;
c. Unfavorable LAD artery or PCI (i.e., excessive vessel tortuosity or
chronic total occlusion).
CLASS IIb
1. Hybrid coronary revascularization (defined as the planned combina-
tion of left internal mammary artery-to-LAD artery grafting and PCI
of1 non-LAD coronary arteries) may be reasonable as an alterna-
tive to multivessel PCI or CABG in an attempt to improve the overall
risk-benefit ratio of the procedures. (Level of Evidence: C)
3. Preprocedural Considerations:
Recommendations
Table 4 contains recommendations for preprocedural con-
iderations and interventions in patients undergoing PCI.
3.1. Radiation Safety
CLASS I
1. Cardiac catheterization laboratories should routinely record rele-
Table 4. Summary of Recommendations for Preprocedural Con
Recommendations
Contrast-induced AKI
Patients should be assessed for risk of contrast-induced AKI before PCI.
Patients undergoing cardiac catheterization with contrast media should rec
adequate preparatory hydration.
In patients with CKD (creatinine clearance 60 mL/min), the volume of con
media should be minimized.
Administration of N-acetyl-L-cysteine is not useful for the prevention of
contrast-induced AKI.
Anaphylactoid reactions
Patients with prior evidence of an anaphylactoid reaction to contrast media
receive appropriate prophylaxis before repeat contrast administration.
In patients with a prior history of allergic reactions to shellfish or seafood,
anaphylactoid prophylaxis for contrast reaction is not beneficial.
Statins
Administration of a high-dose statin is reasonable before PCI to reduce the
periprocedural MI.
Bleeding risk
All patients should be evaluated for risk of bleeding before PCI.
CKD
In patients undergoing PCI, the glomerular filtration rate should be estimate
dosage of renally cleared medications should be adjusted.
Aspirin
Patients already on daily aspirin therapy should take 81 mg to 325 mg bef
Patients not on aspirin therapy should be given nonenteric aspirin 325 mg
AKI indicates acute kidney injury; CKD, chronic kidney disease; COR, class of recommendation;
intervention.vant available patient procedural radiation dose data (e.g., total airkerma at the international reference point [Ka,r], air kerma air
product [PKA], fluoroscopy time, number of cine images), and should
define thresholds with corresponding follow-up protocols for pa-
tients who receive a high procedural radiation dose. (Level of
Evidence: C)
3.2. Contrast-Induced Acute Kidney Injury
CLASS I
1. Patients should be assessed for risk of contrast-induced acute
kidney injury before PCI (118,119). (Level of Evidence: C)
2. Patients undergoing cardiac catheterization with contrast media
should receive adequate preparatory hydration (120–123). (Level of
Evidence: B)
3. In patients with CKD (creatinine clearance 60 mL/min), the
volume of contrast media should beminimized (124–126). (Level of
Evidence: B)
CLASS III: NO BENEFIT
1. Administration of N-acetyl-L-cysteine is not useful for the prevention
of contrast-induced acute kidney injury (127–131). (Level of Evi-
dence: A)
3.3. Anaphylactoid Reactions
CLASS I
1. Patients with prior evidence of an anaphylactoid reaction to contrast
media should receive appropriate steroid and antihistamine prophy-
laxis before repeat contrast administration (132–135). (Level of
ations and Interventions in Patients Undergoing PCI
COR LOE References
I C (118,119)
I B (120–123)
I B (124–126)
III: No Benefit A (127–131)
d I B (132–135)
III: No Benefit C (136–138)
f IIa A: Statin naïve (139–145)
B: Chronic statin therapy (146)
I C N/A
the I B (147–149)
I. I B (150–153)
PCI. I B (150,152,153)
vel of evidence; MI, myocardial infarction; N/A, not applicable; and PCI, percutaneous coronarysider
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1. In patients with a prior history of allergic reactions to shellfish or
seafood, anaphylactoid prophylaxis for contrast reaction is not
beneficial (136–138). (Level of Evidence: C)
3.4. Statin Treatment
CLASS IIa
1. Administration of a high-dose statin is reasonable before PCI to
reduce the risk of periprocedural myocardial infarction. (Level of
Evidence: A for statin-naïve patients [139–145]; Level of Evidence: B
for those on chronic statin therapy [146])
3.5. Bleeding Risk
CLASS I
1. All patients should be evaluated for risk of bleeding before PCI.
(Level of Evidence: C)
3.6. PCI in Hospitals
Without On-Site Surgical Backup
CLASS IIa
1. Primary PCI is reasonable in hospitals without on-site cardiac
surgery, provided that appropriate planning for programdevelopment
has been accomplished (155,156). (Level of Evidence: B)
CLASS IIb
1. Elective PCI might be considered in hospitals without on-site cardiac
surgery, provided that appropriate planning for program develop-
ment has been accomplished and rigorous clinical and angiographic
criteria are used for proper patient selection (156–158). (Level of
Evidence: B)
CLASS III: HARM
1. Primary or elective PCI should not be performed in hospitals without
on-site cardiac surgery capabilities without a proven plan for rapid
transport to a cardiac surgery operating room in a nearby hospital or
without appropriate hemodynamic support capability for transfer.
(Level of Evidence: C)
4. Procedural Considerations:
Recommendations
4.1. Vascular Access
CLASS IIa
1. The use of radial artery access can be useful to decrease access site
Table 5. Indications for Coronary Angiography in STEMI
Indications
Immediate coronary angiography
Candidate for primary PCI
Severe heart failure or cardiogenic shock (if suitable revascularization c
Moderate to large area of myocardium at risk and evidence of failed fib
Coronary angiography 3 to 24 h after fibrinolysis
Hemodynamically stable patients with evidence for successful fibrinolys
Coronary angiography before hospital discharge
Stable patients
Coronary angiography at any time
Patients in whom the risks of revascularization are likely to outweigh th
benefits or the patient or designee does not want invasive care
COR indicates class of recommendation; LOE, level of evidence; N/A, not applicable; PCI, perccomplications (159–167). (Level of Evidence: A)4.2. PCI in Specific Clinical Situations
4.2.1. Unstable Angina/Non–ST-Elevation
Myocardial Infarction
CLASS I
1. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in UA/NSTEMI patients who
have refractory angina or hemodynamic or electrical instability
(without serious comorbidities or contraindications to such proce-
dures) (168–170). (Level of Evidence: B)
. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is indicated in initially stabilized UA/
NSTEMI patients (without serious comorbidities or contraindications
to such procedures) who have an elevated risk for clinical events
(169–172). (Level of Evidence: A)
. The selection of PCI or CABG as the means of revascularization in
the patient with acute coronary syndrome (ACS) should generally be
based on the same considerations as those without ACS
(45,170,173,174). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. An early invasive strategy (i.e., diagnostic angiography with intent to
perform revascularization) is not recommended in patients with
extensive comorbidities (e.g., liver or pulmonary failure, cancer) in
whom (Level of Evidence: C)
a. The risks of revascularization and comorbid conditions are likely
to outweigh the benefits of revascularization,
b. There is a low likelihood of ACS despite acute chest pain, or
c. Consent to revascularization will not be granted regardless of the
findings.
4.2.2. ST-Elevation Myocardial Infarction
Table 5 contains indications for coronary angiography in
STEMI.
4.2.2.1. CORONARY ANGIOGRAPHY STRATEGIES IN STEMI
CLASS I
1. A strategy of immediate coronary angiography with intent to per-
form PCI (or emergency CABG) in patients with STEMI is recom-
mended for:
a. Patients who are candidates for primary PCI (155,175–178).
COR LOE References
I A (155,175–178)
te) I B (179,180)
sis IIa B (181,182)
IIa A (183–187)
IIb C N/A
III: No Benefit C N/A
s coronary intervention; and STEMI; ST-elevation myocardial infarction.andida
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suitable candidates for revascularization (179,180). (Level of
Evidence: B)
CLASS IIa
1. A strategy of immediate coronary angiography (or transfer for
immediate coronary angiography) with intent to perform PCI is
reasonable for patients with STEMI, a moderate to large area of
myocardium at risk, and evidence of failed fibrinolysis (181,182).
(Level of Evidence: B)
2. A strategy of coronary angiography (or transfer for coronary angiog-
raphy) 3 to 24 hours after initiating fibrinolytic therapy with intent to
perform PCI is reasonable for hemodynamically stable patients with
STEMI and evidence for successful fibrinolysis when angiography
and revascularization can be performed as soon as logistically
feasible in this time frame (183–187). (Level of Evidence: A)
CLASS IIb
1. A strategy of coronary angiography performed before hospital dis-
charge might be reasonable in stable patients with STEMI who did
not undergo cardiac catheterization within 24 hours of STEMI onset.
(Level of Evidence: C)
CLASS III: NO BENEFIT
1. A strategy of coronary angiography with intent to perform PCI is not
recommended in patients with STEMI in whom the risks of revascu-
larization are likely to outweigh the benefits or when the patient or
designee does not want invasive care. (Level of Evidence: C)
4.2.2.2. PRIMARY PCI OF THE INFARCT ARTERY
CLASS I
1. Primary PCI should be performed in patients within 12 hours of
onset of STEMI (175–178). (Level of Evidence: A)
2. Primary PCI should be performed in patients with STEMI present-
ing to a hospital with PCI capability within 90 minutes of
first medical contact as a systems goal (188,189). (Level of
Evidence: B)
3. Primary PCI should be performed in patients with STEMI present-
ing to a hospital without PCI capability within 120 minutes of first
medical contact as a systems goal (190–192). (Level of Evi-
dence: B)
4. Primary PCI should be performed in patients with STEMI who
develop severe heart failure or cardiogenic shock and are suitable
candidates for revascularization as soon as possible, irrespective of
time delay (179,180). (Level of Evidence: B)
. Primary PCI should be performed as soon as possible in patients
with STEMI and contraindications to fibrinolytic therapy with isch-
emic symptoms for less than 12 hours (193,194). (Level of Evi-
dence: B)
CLASS IIa
1. Primary PCI is reasonable in patients with STEMI if there is clinical
and/or electrocardiographic evidence of ongoing ischemia between
12 and 24 hours after symptom onset (195–197). (Level of Evi-
dence: B)
CLASS IIb
1. Primary PCI might be considered in asymptomatic patients with
STEMI and higher risk presenting between 12 and 24 hours aftersymptom onset. (Level of Evidence: C)CLASS III: HARM
1. PCI should not be performed in a noninfarct artery at the time of
primary PCI in patients with STEMI without hemodynamic compro-
mise (198–202). (Level of Evidence: B)
4.2.2.3. DELAYED OR ELECTIVE PCI IN PATIENTS WITH STEMI
CLASS IIa
1. PCI is reasonable in patients with STEMI and clinical evidence for
fibrinolytic failure or infarct artery reocclusion (181,182). (Level of
Evidence: B)
. PCI is reasonable in patients with STEMI and a patent infarct artery
3 to 24 hours after fibrinolytic therapy (186,187). (Level of Evi-
dence: B)
. PCI is reasonable in patients with STEMI who demonstrate ischemia
on noninvasive testing (203,204). (Level of Evidence: B)
CLASS IIb
1. PCI of a hemodynamically significant stenosis in a patent infarct
artery greater than 24 hours after STEMI may be considered as part
of an invasive strategy (205–209). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. PCI of a totally occluded infarct artery greater than 24 hours after
STEMI should not be performed in asymptomatic patients with 1- or
2-vessel disease if patients are hemodynamically and electrically
stable and do not have evidence of severe ischemia (210–212).
(Level of Evidence: B)
Table 6 contains indications for PCI in STEMI.
4.2.3. Cardiogenic Shock
CLASS I
1. PCI is recommended for patients with acute myocardial infarction
who develop cardiogenic shock and are suitable candidates
(180,213–215). (Level of Evidence: B)
2. A hemodynamic support device is recommended for patients with
cardiogenic shock after STEMI who do not quickly stabilize with
pharmacological therapy (180,216–219). (Level of Evidence: B)
4.2.4. Revascularization Before Noncardiac Surgery
CLASS IIa
1. For patients who require PCI and are scheduled for elective noncar-
diac surgery in the subsequent 12 months, a strategy of balloon
angioplasty, or BMS implantation followed by 4 to 6 weeks of DAPT,
is reasonable (220–226). (Level of Evidence: B)
. For patients with DES whomust undergo urgent surgical procedures
that mandate the discontinuation of DAPT, it is reasonable to
continue aspirin if possible and restart the P2Y12 inhibitor as soon
as possible in the immediate postoperative period (222,227). (Level
of Evidence: C)
CLASS III: HARM
1. Routine prophylactic coronary revascularization should not be per-
formed in patients with stable CAD before noncardiac surgery
(228,229). (Level of Evidence: B)
2. Elective noncardiac surgery should not be performed in the 4 to 6
weeks after balloon angioplasty or BMS implantation or the 12
months after DES implantation in patients in whom the P2Y12
inhibitor will need to be discontinued perioperatively (107,225,230,231). (Level of Evidence: B)
3rcutane
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CLASS I
1. Before implantation of DES, the interventional cardiologist should
discuss with the patient the need for and duration of DAPT and the
ability of the patient to comply with and tolerate DAPT (232). (Level
of Evidence: C)
2. DES are useful as an alternative to BMS to reduce the risk of
restenosis in cases in which the risk of restenosis is increased and
the patient is likely to be able to tolerate and comply with prolonged
DAPT (Level of Evidence: A for elective PCI [233–237]; Level of
Evidence: C for UA/NSTEMI [235]; Level of Evidence: A for STEMI
[235,236,238–240]).
3. Balloon angioplasty or BMS should be used in patients with high
bleeding risk, inability to comply with 12 months of DAPT, or
anticipated invasive or surgical procedures within the next 12
months, during which time DAPT may be interrupted (107,241–243).
(Level of Evidence: B)
CLASS III: HARM
1. PCI with coronary stenting should not be performed if the patient is
not likely to be able to tolerate and comply with DAPT (107–110).
(Level of Evidence: B)
2. DES should not be implanted if the patient is not likely to be able to
tolerate and comply with prolonged DAPT or this cannot be deter-
mined before stent implantation (107,241–243). (Level of Evi-
dence: B)
4.4. Adjunctive Diagnostic Devices
4.4.1. Fractional Flow Reserve
CLASS IIa
1. Fractional flow reserve is reasonable to assess angiographic inter-
mediate coronary lesions (50% to 70% diameter stenosis) and can
be useful for guiding revascularization decisions in patients with
Table 6. Indications for PCI in STEMI
Indications
Primary PCI*
STEMI symptoms within 12 h
Severe heart failure or cardiogenic shock
Contraindications to fibrinolytic therapy with ischemic symptoms 12 h
Clinical and/or electrocardiographic evidence of ongoing ischemia betwe
symptom onset
Asymptomatic patients presenting between 12 and 24 h after symptom
Noninfarct artery PCI at the time of primary PCI in patients without hemo
compromise
Delayed or elective PCI in patients with STEMI
Clinical evidence for fibrinolytic failure or infarct artery reocclusion
Patent infarct artery 3 to 24 h after fibrinolytic therapy
Ischemia on noninvasive testing
Hemodynamically significant stenosis in a patent infarct artery 24 h af
Totally occluded infarct artery 24 h after STEMI in a hemodynamically
patient without evidence of severe ischemia
*Systems goal of performing primary PCI within 90 min of first medical contact when the patient prese
to a hospital without PCI capability (190–192) (Class I; LOE: B).
COR indicates class of recommendation; LOE, level of evidence; N/A, not applicable; PCI, peSIHD (89,244–247). (Level of Evidence: A)4.4.2. Intravascular Ultrasound
CLASS IIa
1. IVUS is reasonable for the assessment of angiographically indeter-
minant left main CAD (248–250). (Level of Evidence: B)
2. IVUS and coronary angiography are reasonable 4 to 6 weeks and 1
year after cardiac transplantation to exclude donor CAD, detect
rapidly progressive cardiac allograft vasculopathy, and provide prog-
nostic information (251–253). (Level of Evidence: B)
. IVUS is reasonable to determine the mechanism of stent restenosis
(254). (Level of Evidence: C)
CLASS IIb
1. IVUS may be reasonable for the assessment of non–left main
coronary arteries with angiographically intermediate coronary ste-
noses (50% to 70% diameter stenosis) (248,255,256). (Level of
Evidence: B)
2. IVUS may be considered for guidance of coronary stent implanta-
tion, particularly in cases of left main coronary artery stenting
(249,254,257). (Level of Evidence: B)
3. IVUS may be reasonable to determine the mechanism of stent
thrombosis (254). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. IVUS for routine lesion assessment is not recommended when
revascularization with PCI or CABG is not being contemplated.
(Level of Evidence: C)
4.5. Adjunctive Therapeutic Devices
4.5.1. Coronary Atherectomy
CLASS IIa
1. Rotational atherectomy is reasonable for fibrotic or heavily calcified
lesions that might not be crossed by a balloon catheter or ade-
quately dilated before stent implantation (258,259). (Level of
Evidence: C)
CLASS III: NO BENEFIT
1. Rotational atherectomy should not be performed routinely for de
COR LOE References
I A (175–178)
I B (179,180)
I B (193,194)
and 24 h after IIa B (195–197)
and higher risk IIb C N/A
ic III: Harm B (198–202)
IIa B (181,182)
IIa B (186,187)
IIa B (203,204)
EMI IIb B (205–209)
asymptomatic III: No Benefit B (210–212)
hospital with PCI capability (188,189) (Class I; LOE: B) and within 120 min when the patient presents
ous coronary intervention; and STEMI, ST-elevation myocardial infarction.en 12
onset
dynam
ter ST
stable
nts to anovo lesions or in-stent restenosis (260–263). (Level of Evidence: A)
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CLASS IIa
1. Aspiration thrombectomy is reasonable for patients undergoing
primary PCI (264–266). (Level of Evidence: B)
4.5.3. Laser Angioplasty
CLASS IIb
1. Laser angioplasty might be considered for fibrotic or moderately
calcified lesions that cannot be crossed or dilated with conventional
balloon angioplasty (267). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Laser angioplasty should not be used routinely during PCI
(260,262,268). (Level of Evidence: A)
4.5.4. Cutting Balloon Angioplasty
CLASS IIb
1. Cutting balloon angioplasty might be considered to avoid slippage-
induced coronary artery trauma during PCI for in-stent restenosis or
ostial lesions in side branches (269). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Cutting balloon angioplasty should not be performed routinely
during PCI (260,269,270). (Level of Evidence: A)
4.5.5. Embolic Protection Devices
CLASS I
1. Embolic protection devices should be used during saphenous vein graft
PCI when technically feasible (271–274). (Level of Evidence: B)
4.6. Percutaneous Hemodynamic
Support Devices
Table 7 contains recommendations for antiplatelet and
antithrombin pharmacotherapy at the time of PCI.
CLASS IIb
1. Elective insertion of an appropriate hemodynamic support device as
an adjunct to PCI may be reasonable in carefully selected high-risk
patients. (Level of Evidence: C)
4.6.1. Oral Antiplatelet Therapy
CLASS I
1. Patients already taking daily aspirin therapy should take 81 mg to
325 mg before PCI (150–153). (Level of Evidence: B)
2. Patients not on aspirin therapy should be given nonenteric aspirin 325
mg before PCI (150,152,153). (Level of Evidence: B)
. After PCI, use of aspirin should be continued indefinitely (275-278).
(Level of Evidence: A)
. A loading dose of a P2Y12 receptor inhibitor should be given to
patients undergoing PCI with stenting (279–283) (Level of Evi-
dence: A). Options include
a. Clopidogrel 600 mg (ACS and non-ACS patients) (279–281).
(Level of Evidence: B)
b. Prasugrel 60 mg (ACS patients) (282). (Level of Evidence: B)
c. Ticagrelor 180 mg (ACS patients) (283). (Level of Evidence: B)
5. The loading dose of clopidogrel for patients undergoing PCI after
fibrinolytic therapy should be 300 mg within 24 hours and 600 mg
more than 24 hours after receiving fibrinolytic therapy (280,284).
(Level of Evidence: C)
6. Patients should be counseled on the need for and risks of DAPT
before placement of intracoronary stents, especially DES, and alter-native therapies should be pursued if patients are unwilling or
unable to comply with the recommended duration of DAPT (107).
(Level of Evidence: C)
7. The duration of P2Y12 inhibitor therapy after stent implantation
should generally be as follows:
a. In patients receiving a stent (BMS or DES) during PCI for ACS,
P2Y12 inhibitor therapy should be given for at least 12 months.
Options include clopidogrel 75 mg daily (285), prasugrel 10 mg
daily (282), and ticagrelor 90 mg twice daily (283). (Level of
Evidence: B)
b. In patients receiving DES for a non-ACS indication, clopidogrel
75mg daily should be given for at least 12months if patients are
not at high risk of bleeding (107,232,286). (Level of Evidence: B)
c. In patients receiving BMS for a non-ACS indication, clopidogrel
should be given for a minimum of 1 month and ideally up to 12
months (unless the patient is at increased risk of bleeding; then
it should be given for a minimum of 2 weeks) (107,287). (Level
of Evidence: B)
CLASS IIa
1. After PCI, it is reasonable to use aspirin 81mg per day in preference
to higher maintenance doses (151,288–291). (Level of Evidence: B)
2. If the risk of morbidity from bleeding outweighs the anticipated benefit
afforded by a recommended duration of P2Y12 inhibitor therapy after
stent implantation, earlier discontinuation (e.g.,12months) of P2Y12
inhibitor therapy is reasonable. (Level of Evidence: C)
CLASS IIb
1. Continuation of DAPT beyond 12 months may be considered in
patients undergoing DES implantation (282,283). (Level of Evi-
dence: C)
CLASS III: HARM
1. Prasugrel should not be administered to patients with a prior history
of stroke or transient ischemic attack (282). (Level of Evidence: B)
4.6.2. Intravenous Antiplatelet Therapy
STEMI
CLASS IIa
1. In patients undergoing primary PCI treated with unfractionated
heparin (UFH), it is reasonable to administer a glycoprotein (GP)
IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus
dose tirofiban), whether or not patients were pretreated with clopi-
dogrel (292–298). (For GP IIb/IIIa inhibitor administration in pa-
tients not pretreated with clopidogrel, Level of Evidence: A; for GP
IIb/IIIa inhibitor administration in patients pretreated with clopi-
dogrel, Level of Evidence: C)
CLASS IIb
1. In patients undergoing primary PCI with abciximab, it may be
reasonable to administer intracoronary abciximab (297,299–312).
(Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine precatheterization laboratory (e.g., ambulance or emer-
gency room) administration of GP IIb/IIIa inhibitors as part of an
upstream strategy for patients with STEMI undergoing PCI is not
beneficial (313–320). (Level of Evidence: B)
UA/NSTEMI
CLASS I
1. In UA/NSTEMI patients with high-risk features (e.g., elevated tro-ponin level) not treated with bivalirudin and not adequately pre-
able; P ;
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a GP IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or
high-bolus dose tirofiban) in patients treated with UFH (321–326).
(Level of Evidence: A)
CLASS IIa
1. In UA/NSTEMI patients with high-risk features (e.g., elevated tro-
ponin level) treated with UFH and adequately pretreated with clopi-
dogrel, it is reasonable at the time of PCI to administer a GP IIb/IIIa
inhibitor (abciximab, double-bolus eptifibatide, or high-bolus dose
tirofiban) (324,327). (Level of Evidence: B)
SIHD
CLASS IIa
1. In patients undergoing elective PCI treated with UFH and not
pretreated with clopidogrel, it is reasonable to administer a GP
IIb/IIIa inhibitor (abciximab, double-bolus eptifibatide, or high-bolus
Table 7. Recommendations for Antiplatelet and Antithrombin
COR LOE References
Oral antiplatelet agents
Aspirin I B (150–153,275–278
P2Y12
Inhibitors
I A (279–283)
● Clopidogrel I B (279–281)
● Prasugrel I B (282)
● Ticagrelor I B (283)
GP IIb/IIIa inhibitors (abciximab, double-bolus eptifibatide, high-bolus do
● No clopidogrel
pretreatment
STEMI: IIa A (292–298)
UA/NSTEMI: I A (321–326)
SIHD: IIa B (327–329)
● Clopidogrel
pretreatment
STEMI: IIa C (292–298)
UA/NSTEMI: IIa B (324,327)
SIHD: IIb B (327,330–332)
Antithrombin agents
UFH I C N/A
Bivalirudin I B (333–342)
Enoxaparin IIb B (343–347)
Anti-Xa inhibitors
Fondaparinux III: Harm C (348,349)
ACT indicates activated clotting time; COR, class of recommendation; CVA, cerebrovascular ac
intracoronary; IV, intravenous; LOE, level of evidence; MI, myocardial infarction; N/A, not applic
STEMI, ST-elevation myocardial infarction; TIA, transient ischemic attack; UA/NSTEMI, unstabldose tirofiban) (327–329). (Level of Evidence: B)CLASS IIb
1. In patients undergoing elective PCI with stent implantation treated
with UFH and adequately pretreated with clopidogrel, it might be
reasonable to administer a GP IIb/IIIa inhibitor (abciximab, double-
bolus eptifibatide, or high-bolus dose tirofiban) (327,330–332).
(Level of Evidence: B)
4.6.3. Anticoagulant Therapy
4.6.3.1. USE OF PARENTERAL ANTICOAGULANTS DURING PCI
CLASS I
1. An anticoagulant should be administered to patients undergoing
PCI. (Level of Evidence: C)
4.6.3.2. UNFRACTIONATED HEPARIN
CLASS I
1. Administration of IV UFH is useful in patients undergoing PCI. (Level
acotherapy at the Time of PCI
Relevant Caveats/Comments
N/A
● A loading dose of a P2Y12 inhibitor should be given to patients
undergoing PCI with stenting.
● 600-mg loading dose now recommended.
● Contraindicated in patients with prior TIA/CVA: Class III: Harm; LOE: B.
● Generally not recommended in patients 75 years of age
(see Section 5.7.2 in full text).
● Consideration of using a lower maintenance dose in persons weighing
60 kg suggested by FDA (Section 5.7.2 in full text).
● Issues of patient compliance may be especially important.
ofiban)
● UA/NSTEMI recommendation applies to those with high-risk features.
● GPI use in STEMI may be most appropriate in those with large anterior
MI and/or large thrombus burden.
● IC abciximab administration in STEMI: Class IIb; LOE: B.
● Precatheterization laboratory GPI administration in STEMI: Class III:
No Benefit; LOE: B.
● Recommendations apply to those not at high risk for bleeding
complications.
● Dosing based on whether or not GPI was administered
● Lower bleeding rates associated with bivalirudin are mitigated when used
concomitantly with a GPI.
● Recommendations apply to administration of IV enoxaparin at the time
of PCI for those who have not received prior antithrombin therapy or who
have received “upstream” SC enoxaparin therapy for UA/NSTEMI.
● An additional dose of 0.3 mg/kg IV enoxaparin should be administered
at the time of PCI to patients who have received 2 therapeutic SC
doses (e.g., 1 mg/kg) or received the last SC enoxaparin dose 8 to 12 h
before PCI: Class I; LOE: B.
● Patients treated with SC enoxaparin within 12 h of PCI should not receive
additional treatment with UFH during PCI (“stacking”): Class III: Harm;
LOE: B.
● PCI should not be performed with fondaparinux as the sole antithrombin
agent in patients treated with upstream fondaparinux. An additional
anticoagulant with anti-IIa activity should be administered.
FDA, U.S. Food and Drug Administration; GP, glycoprotein; GPI, glycoprotein IIb/IIIa inhibitor; IC
CI, percutaneous coronary intervention; SC, subcutaneous; SIHD, stable ischemic heart disease
a/non–ST-elevation myocardial infarction; and UFH, unfractionated heparin.Pharm
)
se tir
cident; ,of Evidence: C)
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CLASS I
1. An additional dose of 0.3mg/kg IV enoxaparin should be administered
at the time of PCI to patients who have received fewer than 2 thera-
peutic subcutaneous doses (e.g., 1 mg/kg) or received the last subcu-
taneous enoxaparin dose 8 to 12 hours before PCI (346,350–353).
(Level of Evidence: B)
CLASS IIb
1. Performance of PCI with enoxaparin may be reasonable in patients
either treated with “upstream” subcutaneous enoxaparin for UA/
NSTEMI or who have not received prior antithrombin therapy and
are administered IV enoxaparin at the time of PCI (343–347). (Level
of Evidence: B)
CLASS III: HARM
1. UFH should not be given to patients already receiving therapeutic
subcutaneous enoxaparin (346,354). (Level of Evidence: B)
4.6.3.4. BIVALIRUDIN AND ARGATROBAN
CLASS I
1. For patients undergoing PCI, bivalirudin is useful as an anticoagu-
lant with or without prior treatment with UFH (333–342). (Level of
Evidence: B)
2. For patients with heparin-induced thrombocytopenia, it is recom-
mended that bivalirudin or argatroban be used to replace UFH
(355,356). (Level of Evidence: B)
4.6.3.5. FONDAPARINUX
CLASS III: HARM
1. Fondaparinux should not be used as the sole anticoagulant to
support PCI. An additional anticoagulant with anti-IIa activity should
be administered because of the risk of catheter thrombosis
(348,349). (Level of Evidence: C)
4.6.4. No-Reflow Pharmacological Therapies
CLASS IIa
1. Administration of an intracoronary vasodilator (adenosine, calcium
channel blocker, or nitroprusside) is reasonable to treat PCI-related
no-reflow that occurs during primary or elective PCI (357–372).
(Level of Evidence: B)
4.7. PCI in Specific Anatomic Situations
4.7.1. Chronic Total Occlusions
CLASS IIa
1. PCI of a chronic total occlusion in patients with appropriate
clinical indications and suitable anatomy is reasonable when
performed by operators with appropriate expertise (373–377).
(Level of Evidence: B)
4.7.2. Saphenous Vein Grafts
CLASS I
1. Embolic protection devices should be used during saphenous vein
graft PCI when technically feasible (271–274). (Level of Evi-
dence: B)CLASS III: NO BENEFIT
1. Platelet GP IIb/IIIa inhibitors are not beneficial as adjunctive ther-
apy during saphenous vein graft PCI (232,286,378,379). (Level of
Evidence: B)
CLASS III: HARM
1. PCI is not recommended for chronic saphenous vein graft occlu-
sions (380–382). (Level of Evidence: C)
4.7.3. Bifurcation Lesions
CLASS I
1. Provisional side-branch stenting should be the initial approach in
patients with bifurcation lesions when the side branch is not large and
has only mild or moderate focal disease at the ostium (383–386).
(Level of Evidence: A)
CLASS IIa
1. It is reasonable to use elective double stenting in patients with
complex bifurcationmorphology involving a large side branch where
the risk of side-branch occlusion is high and the likelihood of
successful side-branch reaccess is low (387–390). (Level of Evi-
dence: B)
4.7.4. Aorto-Ostial Stenoses
CLASS IIa
1. IVUS is reasonable for the assessment of angiographically indeter-
minant left main CAD (391,392). (Level of Evidence: B)
2. Use of DES is reasonable when PCI is indicated in patients with an
aorto-ostial stenosis (393,394). (Level of Evidence: B)
4.7.5. Calcified Lesions
CLASS IIa
1. Rotational atherectomy is reasonable for fibrotic or heavily calcified
lesions that might not be crossed by a balloon catheter or ade-
quately dilated before stent implantation (258,259,395). (Level of
Evidence: C)
4.8. PCI in Specific Patient Populations
4.8.1. Chronic Kidney Disease
CLASS I
In patients undergoing PCI, the glomerular filtration rate should be
estimated and the dosage of renally cleared medications should be
adjusted (147–149). (Level of Evidence: B)
4.9. Periprocedural Myocardial
Infarction Assessment
CLASS I
1. In patients who have signs or symptoms suggestive of myocardial
infarction during or after PCI or in asymptomatic patients with
significant persistent angiographic complications (e.g., large side-
branch occlusion, flow-limiting dissection, no-reflow phenomenon,
or coronary thrombosis), creatinine kinase-MB and troponin I or T
should be measured. (Level of Evidence: C)
CLASS IIb
1. Routine measurement of cardiac biomarkers (creatinine kinase-MB
and/or troponin I or T) in all patients after PCI may be reasonable.
(Level of Evidence: C)
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CLASS I
1. Patients considered for vascular closure devices should undergo a
femoral angiogram to ensure their anatomic suitability for deploy-
ment. (Level of Evidence: C)
CLASS IIa
1. The use of vascular closure devices is reasonable for the purposes of
achieving faster hemostasis and earlier ambulation compared with
the use of manual compression (396–399). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. The routine use of vascular closure devices is not recommended for
the purpose of decreasing vascular complications, including bleed-
ing (396–401). (Level of Evidence: B)
5. Postprocedural Considerations:
Recommendations
Postprocedural considerations in patients undergoing PCI
are discussed below and summarized in Table 8. Some
recommendations and text regarding DAPT in Section
5.7.2 of the full-text guideline (4) are intentionally repeated
in this section for reader ease of use.
5.1. Postprocedural Antiplatelet Therapy
CLASS I
1. After PCI, use of aspirin should be continued indefinitely (275–278).
(Level of Evidence: A)
2. The duration of P2Y12 inhibitor therapy after stent implantation
should generally be as follows:
a. In patients receiving a stent (BMS or DES) during PCI for ACS,
P2Y12 inhibitor therapy should be given for at least 12 months.
Options include clopidogrel 75 mg daily (285), prasugrel 10 mg
daily (282), and ticagrelor 90 mg twice daily (283). (Level of
Evidence: B)
b. In patients receiving DES for a non-ACS indication, clopidogrel
75 mg daily should be given for at least 12 months if the
patient is not at high risk of bleeding (107,232,286). (Level of
Evidence: B)
c. In patients receiving BMS for a non-ACS indication, clopidogrel
should be given for a minimum of 1 month and ideally up to 12
months (unless the patient is at increased risk of bleeding; then
it should be given for a minimum of 2 weeks) (287). (Level of
Evidence: B)
. Patients should be counseled on the importance of compliance with
DAPT and that therapy should not be discontinued before discus-
sion with their cardiologist (107). (Level of Evidence: C)
CLASS IIa
1. After PCI, it is reasonable to use aspirin 81 mg per day in
preference to higher maintenance doses (151,288–291). (Level
of Evidence: B)
2. If the risk of morbidity from bleeding outweighs the anticipated
benefit afforded by a recommended duration of P2Y12 inhibitor
therapy after stent implantation, earlier discontinuation (e.g.,
12 months) of P2Y12 inhibitor therapy is reasonable. (Level of
Evidence: C)CLASS IIb
1. Continuation of clopidogrel, prasugrel or ticagrelor beyond 12
months may be considered in patients undergoing placement of
DES (282,283). (Level of Evidence: C)
5.1.1. Proton Pump Inhibitors and
Antiplatelet Therapy
CLASS I
1. Proton pump inhibitors should be used in patients with a history of
prior gastrointestinal bleeding who require DAPT (402). (Level of
Evidence: C)
CLASS IIa
1. Use of proton pump inhibitors is reasonable in patients with an
increased risk of gastrointestinal bleeding (e.g., advanced age,
concomitant use of warfarin, steroids, nonsteroidal anti-
inflammatory drugs,Helicobacter pylori infection) who require DAPT
(402). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Routine use of a proton pump inhibitor is not recommended for
patients at low risk of gastrointestinal bleeding, who havemuch less
potential to benefit from prophylactic therapy (402). (Level of
Evidence: C)
5.1.2. Clopidogrel Genetic Testing
CLASS IIb
1. Genetic testing might be considered to identify whether a patient at
high risk for poor clinical outcomes is predisposed to inadequate
platelet inhibition with clopidogrel (434). (Level of Evidence: C)
2. When a patient predisposed to inadequate platelet inhibition with
clopidogrel is identified by genetic testing, treatment with an alter-
nate P2Y12 inhibitor (e.g., prasugrel or ticagrelor) might be consid-
ered (434). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. The routine clinical use of genetic testing to screen patients treated
with clopidogrel who are undergoing PCI is not recommended (434).
(Level of Evidence: C)
5.1.3. Platelet Function Testing
CLASS IIb
1. Platelet function testing may be considered in patients at high risk
for poor clinical outcomes (434). (Level of Evidence: C)
2. In patients treated with clopidogrel with high platelet reactivity,
alternative agents, such as prasugrel or ticagrelor, might be consid-
ered (434). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. The routine clinical use of platelet function testing to screen pa-
tients treated with clopidogrel who are undergoing PCI is not
recommended (434). (Level of Evidence: C)
5.2. Restenosis
CLASS I
1. Patients who develop clinical restenosis after balloon angioplasty
should be treated with BMS or DES if anatomic factors are appro-
priate and if the patient is able to comply with and tolerate DAPT
(435). (Level of Evidence: B)
2. Patients who develop clinical restenosis after BMS should be
treated with DES if anatomic factors are appropriate and the patient
ation; D
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CLASS IIa
1. IVUS is reasonable to determine the mechanism of stent restenosis
Table 8. Postprocedural Recommendations for Patients Underg
Recommendations
Aspirin
After PCI, use of aspirin should be continued indefinitely.
After PCI, it is reasonable to use aspirin 81 mg/d in preference to higher mainten
P2Y12 inhibitors
In patients receiving a stent (BMS or DES) during PCI for ACS, P2Y12 inhibitor
should be given for at least 12 mo. Options include clopidogrel 75 mg/d, pr
mg/d, and ticagrelor 90 mg twice daily.
In patients receiving DES for a non-ACS indication, clopidogrel 75 mg/d shoul
for at least 12 mo if patients are not at high risk of bleeding.
In patients receiving BMS for a non-ACS indication, clopidogrel should be give
minimum of 1 mo and ideally up to 12 mo (unless the patient is at increas
bleeding; then it should be given for a minimum of 2 wk).
Patients should be counseled on the importance of compliance with DAPT an
therapy should not be discontinued before discussion with their cardiologist
PPIs should be used in patients with a history of prior GI bleeding who require
If the risk of morbidity from bleeding outweighs the anticipated benefit afford
recommended duration of P2Y12 inhibitor therapy after stent implantation,
discontinuation (e.g., 12 mo) of P2Y12 inhibitor therapy is reasonable.
Use of PPIs is reasonable in patients with an increased risk of GI bleeding (e.g
age, concomitant use of warfarin, steroids, NSAIDs, Helicobacter pylori infe
require DAPT.
Continuation of clopidogrel, prasugrel, or ticagrelor beyond 12 mo may be con
patients undergoing placement of DES.
Routine use of a PPI is not recommended for patients at low risk of GI bleedin
much less potential to benefit from prophylactic therapy.
Exercise testing
For patients entering a formal cardiac rehabilitation program after PCI, treadm
testing is reasonable.
Routine periodic stress testing of asymptomatic patients after PCI without spe
indications should not be performed.
Cardiac rehabilitation
Medically supervised exercise programs (cardiac rehabilitation) should be reco
to patients after PCI, particularly for patients at moderate to high risk for w
supervised exercise training is warranted.
Secondary prevention (recommendations included from the 2011 AHA/ACCF
Lipid management with lifestyle modification and
lipid-lowering pharmacotherapy
Lifestyle modificatio
Statin therapy
Statin therapy whic
cholesterol to 1
and achieves at l
lowering of LDL c
Statin therapy whic
cholesterol to 7
very high-risk* pa
Blood pressure control (with a blood pressure
goal of 140/90 mm Hg)
Lifestyle modificatio
Pharmacotherapy
Diabetes management (e.g., lifestyle modification and pharmacotherapy) coo
with the patient’s primary care physician and/or endocrinologist
Complete smoking cessation
*Presence of established cardiovascular disease plus 1) multiple major risk factors (especially di
risk factors of the metabolic syndrome (especially high triglycerides 200 mg/dL plus non–HD
ACS indicates acute coronary syndromes; BMS, bare-metal stent(s); COR, class of recommend
lipoprotein; LDL, low-density lipoprotein; LOE, level of evidence; N/A, not applicable; NSAID, nons(254). (Level of Evidence: C)CLASS IIb
1. Patients who develop clinical restenosis after DES may be consid-
ered for repeat PCI with balloon angioplasty, BMS, or DES contain-
ing the same drug or an alternative antiproliferative drug if ana-
tomic factors are appropriate and the patient is able to comply with
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CLASS IIa
1. In patients entering a formal cardiac rehabilitation program after
PCI, treadmill exercise testing is reasonable. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Routine periodic stress testing of asymptomatic patients after PCI
without specific clinical indications should not be performed (403).
(Level of Evidence: C)
5.2.2. Cardiac Rehabilitation
CLASS I
1. Medically supervised exercise programs (cardiac rehabilitation)
should be recommended to patients after PCI, particularly for
moderate- to high-risk patients for whom supervised exercise train-
ing is warranted (404–412). (Level of Evidence: A)
6. Quality and Performance Considerations:
Recommendations
6.1. Quality and Performance
CLASS I
1. Every PCI program should operate a quality-improvement program
that routinely 1) reviews quality and outcomes of the entire pro-
gram; 2) reviews results of individual operators; 3) includes risk
adjustment; 4) provides peer review of difficult or complicated
cases; and 5) performs random case reviews. (Level of Evidence: C)
. Every PCI program should participate in a regional or national PCI
registry for the purpose of benchmarking its outcomes against
current national norms. (Level of Evidence: C)
6.2. Certification and Maintenance
of Certification
CLASS IIa
1. It is reasonable for all physicians who perform PCI to participate in
the American Board of Internal Medicine interventional cardiology
board certification and maintenance of certification program. (Level
of Evidence: C)
6.3. Operator and Institutional
Competency and Volume
CLASS I
1. Elective/urgent PCI should be performed by operators with an
acceptable annual volume (75 procedures) at high-volume cen-
ters (400 procedures) with on-site cardiac surgery (439,440).
(Level of Evidence: C)
2. Elective/urgent PCI should be performed by operators and institu-
tions whose current risk-adjusted outcomes statistics are compara-
ble to those reported in contemporary national data registries.
(Level of Evidence: C)
3. Primary PCI for STEMI should be performed by experienced opera-
tors who perform more than 75 elective PCI procedures per year
and, ideally, at least 11 PCI procedures for STEMI per year. Ideally,
these procedures should be performed in institutions that per-
form more than 400 elective PCIs per year and more than 36
primary PCI procedures for STEMI per year (439,441–444).
(Level of Evidence: C)CLASS IIa
1. It is reasonable that operators with acceptable volume (75 PCI
procedures per year) perform elective/urgent PCI at low-volume
centers (200 to 400 PCI procedures per year) with on-site cardiac
surgery (439). (Level of Evidence: C)
. It is reasonable that low-volume operators (75 PCI procedures per
year) perform elective/urgent PCI at high-volume centers (400
PCI procedures per year) with on-site cardiac surgery. Ideally, oper-
ators with an annual procedure volume of fewer than 75 procedures
per year should only work at institutions with an activity level of
more than 600 procedures per year. Operators who perform fewer
than 75 procedures per year should develop a defined mentoring
relationship with a highly experienced operator who has an annual
procedural volume of at least 150 procedures. (Level of Evidence: C)
CLASS IIb
1. The benefit of primary PCI for STEMI patients eligible for fibrinolysis
when performed by an operator who performs fewer than 75
procedures per year (11 PCIs for STEMI per year) is not well
established. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. It is not recommended that elective/urgent PCI be performed by
low-volume operators (75 procedures per year) at low-volume
centers (200 to 400 procedures per year) with or without on-site
cardiac surgery. An institution with a volume of fewer than 200
procedures per year, unless in a region that is underserved because
of geography, should carefully consider whether it should continue
to offer this service (439). (Level of Evidence: C)
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